XML 14 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Product revenues $ 731 $ 591
Cost of product revenues 273 410
Amortization of intangible assets 306 306
Gross (loss) profit 152 (125)
Development revenues:    
Government contracts and other 917 1,018
Total development revenues 917 1,018
Operating expenses:    
Research and development 2,499 3,289
Sales and marketing 678 939
General and administrative 2,244 2,108
Total operating expenses 5,421 8,022
Operating loss (4,352) (7,129)
Other income (expense):    
Interest income 14 11
Interest expense (423) (591)
Other income, net 352 165
Total other expense (57) (415)
Net loss $ (4,409) $ (7,544)
Basic and diluted net loss per share $ (0.07) $ (0.33)
Basic and diluted weighted average shares used in calculating net loss per share 60,177,911 22,736,366
Comprehensive loss:    
Net loss $ (4,409) $ (7,544)
Other comprehensive loss – foreign currency translation adjustments (281) (60)
Comprehensive loss (4,690) (7,604)
Azaya Therapeutics, Inc. [Member]    
Operating expenses:    
In process research and development acquired from Azaya Therapeutics $ 0 $ 1,686